Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2021
NervGen completes C$9.2 million financing
NervGen Pharma completed its public offering, including the full exercise of the underwriters' over-allotment option, for aggregate gross proceeds of C$9.2 million.
2021
NervGen prices public equity offering
NervGen announced the pricing of a previously announced public offering of up to 3.25 million units at C$1.55 per unit, for gross proceeds of up to approximately C$5 million. The offering remained subject to closing conditions and was expected to close during the week of May 12, 2021.
2019
NervGen appoints Paul Brennan as President and CEO
NervGen Pharma appointed Paul Brennan President and CEO, replacing Ernest Wong, who would continue to support the company as a consultant. Brennan was also appointed to NervGen's Board of Directors.